The magnitudes of the OS, PFS, and ORR benefits with nivolumab–ipilimumab observed in this patient subgroup were greater for those with tumor PD-L1 expression ≥1% versus those with tumor PD-L1 expression <1% [35]. The gene discussed is CD274; the disease is neoplasm.